Fumito Wada

CEO & Co-Founder at Liid Pharmaceuticals

Speaker

Fumito has been researching the therapeutic applications of Bridged Nucleic Acids (BNAs), including LNA, at Osaka University since 2012. Following this, he advanced his research at the National Cerebral and Cardiovascular Center, focusing on the preclinical development of ASOs for dyslipidemia. Based on these experiences, he founded Liid Pharmaceuticals, Inc. A strong advocate for the potential of BNA-based drugs, he is committed to advancing their clinical applications.